Skip to main content
All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for ELI LILLY & COMPANY · Pharmaceutical/ Health Products

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 3
  • JEANNE HAGGERTY
    Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
  • CHRISTOPHER E. WILCOX
    Previously held: LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
  • ROBERT BUTORA
    Previously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 7
Taxation/Internal Revenue Code

International and domestic tax issues. Implementation of PL 119-21.

Health Issues

340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. SAFE Drugs Act (HR6509/S3794). FDA actions on drug compounding and illicit drugs. Issues related to TrumpRX. Alzheimer's Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267).

Medicare/Medicaid

Issues related to drug pricing; Issues related to reimbursement of insulin products and obesity medications: Issues related to most favored nation pricing polices.

Budget/Appropriations

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

Trade (domestic/foreign)

Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights. Issues related to China WRT the BINSA bill.

Defense

Issues related to pharmaceutical manufacturing and development. Issues related to China WRT the BINSA bill.

Pharmacy

Drug importation, prescription drug safety, value and access.

 Bills named in this filing 3

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem